Promising ALS drug shows potential in Late-Stage trial
Disease control
Completed
This phase 3 trial tested a drug called Lenzumestrocel (Neuronata-R) in 123 people with ALS, a progressive nerve disease. The goal was to see if repeated doses could slow the disease and improve survival compared to a placebo. The study measured how well patients functioned and h…
Phase: PHASE3 • Sponsor: Corestemchemon, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC